A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.

Completed · Phase 1 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.

Key facts

Study ID

NCT07546214

Run by

Sun Pharmaceutical Industries, Inc.

People needed

575

Starts

2025-10-13

Expected to finish

2026-03-18

Last updated by the study team

2026-04-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or non-pregnant female aged ≥ 18 years with a clinical diagnosis of plaque psoriasis.
• Subjects must have provided IRB approved written informed consent.
• Subjects must have a clinical diagnosis of stable (at least 6 months) plaque psoriasis involving 3% to 20% body surface area (BSA), not including the face, scalp, groin, palms, fingernails, toenails, and soles in the BSA calculation.
• Subjects must have plaque psoriasis with a Physician's Global Assessment (PGA) score of 2 (mild), 3 (moderate), or 4 (severe)

You may not qualify if…

• Female Subjects who are pregnant, nursing, or planning to become pregnant during study participation.
• Subjects with a known hypersensitivity to tapinarof or to any ingredients in the study drugs.
• Subjects with a current diagnosis of drug-induced psoriasis or unstable forms of psoriasis, including guttate, erythrodermic, exfoliative, or pustular psoriasis.
• Subjects with spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis as determined by the investigator.

Where it is running

• Sun Pharmaceutical Industries, Inc. — Hawthorne, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.